Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Impact of pharmacogenomics and metabolism on the effectiveness and toxicity of racemic ketamine in palliative care and chronic pain patients


To see complete record on anzctr.org.au, please visit this link

Id: ACTRN12613000327785

Organisation Name: Andrew Somogyi

Overal Status: Completed

Start Date: 29/08/2012

Brief Summary: The primary purpose is to determine whether the effectiveness of ketamine and its toxicity are related to the circulating plasma concentrations of ketamine and/or its active metabolite norketamine.
The study hypothesis is that there is a plasma concentration window for ketamine, below which it is ineffective to control pain and above which it produces adverse effects, and that the concentration is dependent on the patient's genotype for CYP2B6

Countries:
  • Australia


Total execution time in seconds: 0.08308219909668